[EN] MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS<br/>[FR] DERIVES DE QUINAZOLINE MACROCYCLIQUE UTILISES COMME AGENTS ANTIPROLIFERATIFS
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2004105765A1
公开(公告)日:2004-12-09
The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents O, CH2, NH or S; in particular Z represents NH; Y represents -C3-9alkyl-, -C3-9alkenyl-, -C3-9alkynyl-, -C3-7alkyl-CO-NH- optionally substituted with amino, mono- or di(C1-4alkyl)amino or C1-4 alkyloxycarbonylamino-, -C3-7alkenyl-CO-NH- optionally substituted with amino, mono- or di(C1-4alkyl)amino- or C1-4alkyloxycarbonylamino-, C1-5alkyl-oxy-C1-5alkyl-, -C1-5alkyl NR13-, -C1-5alkyl-, -C1-5alkyl-NR14-CO-C1-5alkyl-, -C1-5alkyl-CO NR15-C1-5alkyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO-, -C1-3alkyl-NH-CS-Het20-, -C1-3alkyl-NH-CO-Het20-, -C1-2alkyl-CO-Het21-CO-, -Het22-CH2-CO-NH-C1-3alkyl-, -CO-NH-C1-6alkyl-, -NH-CO-C1-6alkyl-, -CO-C1-7alkyl-, -C1-7alkyl-CO-, -C1-6alkyl-CO-C1-6alkyl-, -C1-2alkyl-NH-CO-CR16R17-NH-, -C1-2alkyl-CO-NH-CR18R19-CO-, -C1-2alkyl-CO-NR20-C1-3alkyl-CO-, C1-2alkyl-NR21-CH2-CO-NH-C1-3alkyl-, or -NR22-CO-C1-3alkyl-NH-; X1 represents a direct bond, O or -O-C1-2alkyl-, CO, -CO-C1-2alkyl-, NR11, -NR11-C1-2alkyl-, CH2-, -O-N=CH- or -C1-2alkyl-; X2 represents a direct bond, O, -O-C1-2alkyl-, CO, -CO-C1-2alkyl-, NR12, -NR12-C1-2alkyl-, -CH2-, -O-N=CH- or -C1-2alkyl-. The growth inhibitory effect anti-tumour activity of the present compounds has been demonstrated in vitro, in enzymatic assays on the receptor tyrosine kinase EGFR.
本发明涉及公式(I)的化合物,其N-氧化物形式,药用可接受的加合物盐及其立体化异构形式,其中Z代表O、CH2、NH或S;特别是Z代表NH;Y代表-C3-9烷基,-C3-9烯基,-C3-9炔基,-C3-7烷基-CO-NH-(可选择地被氨基,单或双(C1-4烷基)氨基或C1-4烷氧羰氨基取代),-C3-7烯基-CO-NH-(可选择地被氨基,单或双(C1-4烷基)氨基或C1-4烷氧羰氨基取代),C1-5烷氧基-C1-5烷基,-C1-5烷基-NR13-,-C1-5烷基,-C1-5烷基-NR14-CO-C1-5烷基,-C1-5烷基-CO NR15-C1-5烷基,-C1-6烷基-CO-NH-,-C1-6烷基-NH-CO-,-C1-3烷基-NH-CS-Het20-,-C1-3烷基-NH-CO-Het20-,-C1-2烷基-CO-Het21-CO-,-Het22-CH2-CO-NH-C1-3烷基-,-CO-NH-C1-6烷基-,-NH-CO-C1-6烷基-,-CO-C1-7烷基-,-C1-7烷基-CO-,-C1-6烷基-CO-C1-6烷基-,-C1-2烷基-NH-CO-CR16R17-NH-,-C1-2烷基-CO-NH-CR18R19-CO-,-C1-2烷基-CO-NR20-C1-3烷基-CO-,C1-2烷基-NR21-CH2-CO-NH-C1-3烷基-,或-NR22-CO-C1-3烷基-NH-;X1代表直接键,O或-O-C1-2烷基-,CO,-CO-C1-2烷基-,NR11,-NR11-C1-2烷基-,CH2-,-O-N=CH-或-C1-2烷基-;X2代表直接键,O,-O-C1-2烷基-,CO,-CO-C1-2烷基-,NR12,-NR12-C1-2烷基-,-CH2-,-O-N=CH-或-C1-2烷基-。本发明化合物的生长抑制效应和抗肿瘤活性已在体外实验中,在EGFR受体酪氨酸激酶的酶促活性测定中得到证明。